Detection of pTDP‐43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis

• Published in: Brain pathology (Zurich, Switzerland) Vol. 34; no. 6; pp. e13261 - n/a
• Main Authors: Zhang, Qi‐Jie, Lin, Jie, Wang, You‐Liang, Chen, Long, Ding, Ying, Zheng, Fu‐Ze, Song, Huan‐Huan, Lv, Ao‐Wei, Li, Yu‐Ying, Guo, Qi‐Fu, Lin, Min‐Ting, Hu, Wei, Xu, Liu‐Qing, Zhao, Wen‐Long, Fang, Ling, Cui, Meng‐Chao, Fu, Zhi‐Fei, Chen, Wan‐Jin, Zhang, Jing, Wang, Zhi‐Qiang, Wang, Ning, Fu, Ying
• Format: Journal Article
• Language: English
• Published: Switzerland John Wiley & Sons, Inc 01.11.2024; John Wiley and Sons Inc
• Subjects: Adult; Aged; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - diagnosis; Amyotrophic Lateral Sclerosis - genetics; Amyotrophic Lateral Sclerosis - metabolism; Amyotrophic Lateral Sclerosis - pathology; Bioaccumulation; Biomarkers; Biomarkers - metabolism; Biopsy; Biopsy - methods; C9orf72 Protein - genetics; Cohort Studies; Diagnosis; diagnostic marker; Diagnostic systems; DNA-Binding Proteins - metabolism; Electromyography; Female; Humans; Male; Middle Aged; Motor neurons; muscle biopsy; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Muscles; Neurodegenerative diseases; pathology; phosphorylated TDP‐43; Phosphorylation; Quadriceps muscle; Sarcolemma; Skeletal muscle; Superoxide dismutase; phosphorylated TDP‐43; pathology; diagnostic marker; muscle biopsy; amyotrophic lateral sclerosis
• ISSN: 1015-6305; 1750-3639; 1750-3639
• DOI: 10.1111/bpa.13261

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, pathologically characterized by TDP‐43 aggregates. Recent evidence has been indicated that phosphorylated TDP‐43 (pTDP‐43) is present not only in motor neurons but also in muscle tissues. However, it is unclear whether testing pTDP‐43 aggregation in muscle tissue would assist in the diagnosis of ALS. We propose three key questions: (i) Is aggregation of pTDP‐43 detectable in routine biopsied muscles? (ii) Can detection of pTDP‐43 aggregation discriminate between ALS and non‐ALS patients? (iii) Can pTDP‐43 aggregation be observed in the early stages of ALS? We conducted a diagnostic study comprising 2 groups: an ALS group in which 18 cases underwent muscle biopsy screened from a registered ALS cohort consisting of 802 patients and a non‐ALS control group, in which we randomly selected 54 muscle samples from a biospecimen bank of 684 patients. Among the 18 ALS patients, 3 patients carried pathological GGGGCC repeats in the C9ORF72 gene, 2 patients carried SOD1 mutations, and 7 patients were at an early stage with only one body region clinically affected. The pTDP‐43 accumulation could be detected in routine biopsied muscles, including biceps brachii, deltoid, tibialis anterior, and quadriceps. Abnormal aggregation of pTDP‐43 was present in 94.4% of ALS patients (17/18) compared to 29.6% of non‐ALS controls (16/54; p < 0.001). The pTDP‐43 aggregates were mainly close to the sarcolemma. Using a semi‐quantified pTDP‐43 aggregates score, we applied a cut‐off value of 3 as a diagnostic biomarker, resulting in a sensitivity of 94.4% and a specificity of 83.3%. Moreover, we observed that accumulation of pTDP‐43 occurred in muscle tissues prior to clinical symptoms and electromyographic lesions. Our study provides proof‐of‐concept for the detection of pTDP‐43 accumulation via routine muscle biopsy which may serve as a novel biomarker for diagnosis of ALS. To explore whether testing pTDP‐43 aggregation in muscle tissue would assist in the diagnosis of ALS, we conducted a diagnostic study in 18 ALS patients and 54 randomly matched controls from ALS and muscular disease cohorts. Our results indicated that pTDP‐43 was more prone to accumulation in ALS patients, enabling differentiation between ALS and non‐ALS patients with high sensitivity and specificity. Moreover, we observed that accumulation of pTDP‐43 occurred in muscle tissues prior to clinical symptoms and electromyographic lesions.